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In a large, multicenter, contemporary, 8-year, cohort study, one 
third of allogeneic-hematopoietic cell transplant (HCT) recipi-
ents with Pseudomonas aeruginosa (PSA) infection developed a 
recurrent infection within 3 months. Antibiotic treatment du-
ration of ≥14 days was the only significantly associated variable 
with reduced recurrence rates of PSA infections in allogeneic-
HCT recipients.
Keywords.  allogeneic hematopoietic cell transplant recipi-
ents; duration treatment; Pseudomonas aeruginosa; recurrent 
infection.
Pseudomonas aeruginosa (PSA) is the most commonly isolated 
pathogen in lower respiratory tract (LRT), and the third most 
common Gram-negative organism in bloodstream infections 
(BSI) during the first 3 and 6  months after allogeneic hema-
topoietic cell transplantation (allo-HCT), respectively [1, 2]. 
Furthermore, the prevalence of PSA-antimicrobial resistance 
has been steadily increasing [2]. In a recent European study, 38% 
of PSA isolates were resistant to carbapenems and 29% were 
multidrug resistant (MDR) [2]. These data are relevant, consid-
ering that the mortality attributable to MDR-PSA infections in 
patients with hematologic malignancies reaches 40% [3].
There are limited data on the management of PSA BSI 
and/or LRT infection (LRTI) in allo-HCT recipients. 
Retrospective data suggested that treatments of <14 days for 
PSA LRTI were associated with a higher relapse rate (6 of 19, 
31.6%) compared with longer courses (4 of 40, 10%; P = .06) 
[4]. Although not conclusive, these data represent the only 
available evidence to suggest that longer treatment courses 
may be required in allo-HCT recipients with PSA infections. 
We conducted a retrospective, multicenter cohort study using 
the Swiss Transplant Cohort Study (STCS) to evaluate the in-
cidence and timing of primary and recurrent PSA BSI and/or 




This was a retrospective cohort study including all adult allo-
HCT recipients between January 2011 and May 2018 with 
available signed informed consent form participating in the 
STCS [5]. The study was approved by the relevant Ethical 
Committees.
Inclusion and Exclusion Criteria
Cases included all adult (≥18 years) allo-HCT recipients with 
a proven diagnosis of PSA BSI and/or LRTI and ≥6-month 
follow-up post-HCT. For patients who received >1 allo-HCT 
recipients, the latest transplant was considered. Patients were 
excluded if data on PSA-active treatment were not available.
Outcomes
The primary outcome was the incidence of recurrent PSA 
infection within the first 90-days posttreatment completion 
of the primary PSA infection. The following secondary out-
comes were assessed: (1) time to first recurrence of PSA in-
fection, (2) predictors of PSA infection recurrence, and (3) 
all-cause mortality.
Definitions
Proven PSA BSI was defined as the presence of ≥1 blood cul-
ture positive for PSA [4]. Pseudomonas aeruginosa LRTI was 
defined based on previously described clinical, radiological, 
and microbiological criteria [4]. Primary PSA infection was de-
fined as the first documented episode of a proven PSA infection 
post-HCT. Recurrent infection was defined as PSA infection 
occurring within 90  days after completion of treatment and 
documented resolution of the previous episode. Patients were 
excluded from analyses if they died during or within 7 days after 
the end of treatment of their primary PSA infection. Two phys-
icians (F.O. and D.N.) independently reviewed all cases, without 
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any discrepancies in their assessments. Bacterial, viral, and in-
vasive fungal infections (IFIs) were defined based on the STCS 
and prior consensus guidelines [5, 6].
Data Collection
The following data included in the STCS database were re-
corded: demographics, HCT-associated variables, and post-
HCT infectious complications 1  month before and 3  months 
postdiagnosis of a PSA infection, including bacterial BSI and/
or LRTIs, viral infections, and proven/probable IFI. Specific 
data on PSA infection diagnosis, disease severity, and treatment 
were recorded by chart review.
Statistical Analyses
A χ 2 test and Student t test were used for categorical and con-
tinuous variable comparisons, respectively. Cumulative in-
cidence of primary PSA infection was estimated from HCT 
date to PSA infection among all allo-HCT recipients during 
the study period, whereas the cumulative incidence of re-
current PSA infection was estimated from the date of treat-
ment completion of the primary PSA infection, censoring 
for death and loss to follow-up. Mortality was analyzed 
using the Kaplan-Meier method. A 2-sided P < .05 was con-
sidered statistically significant for all tests. Statistical anal-
ysis was performed using STATA 16.0 (StataCorp, College 
Station, TX).
RESULTS
Incidence of Pseudomonas aeruginosa Infections
Fifty-five patients with primary PSA infections were identified 
among 1314 allo-HCT recipients, with a cumulative incidence 
of 4.2% (Figure  1a). Overall, 22 of 55 (40%), 24 of 55 (44%), 
and 9 of 55 (16%) patients were diagnosed with PSA BSI, LRTI, 
and concomitant BSI and LRTI (BSI + LRTI), respectively. The 
patient baseline characteristics are detailed in Supplementary 
Table 1. Most of available PSA isolates (30 of 48, 62.5%) were 
susceptible to all antibiotic classes tested. Combination antibi-
otic therapy with 2 agents from different classes were admin-
istered during the first 7 days of treatment in 15 of 55 (27.3%) 
patients. Sequential administration of different agents was ob-
served in 36 of 55 (65.5%) patients. Median duration of antibi-
otic treatment for primary PSA infection was 15.5 (interquartile 
range [IQR], 13–29) days. There were no BSIs complicated by 
osteoarticular, endocarditis/endovascular, or central nervous 
system infections.
A total of 12 patients who died either during the treatment 
of the primary PSA infection (N = 8) or within 7  days after 
treatment completion (N = 4) were excluded from recurrent 
infection analyses. Hence, for all subsequent analyses, only 
the remaining 43 patients were used (Supplementary Table 
2). Among them, there were 14 (32.6%) patients who received 
monotherapy with the same agent throughout their treatment 
course, followed by 15 (34.9%) patients who received sequen-
tial treatment only, 12 (27.9%) patients who received both se-
quential and combination treatment, and 2 (4.6%) patients who 
received combination treatment only. Fifteen (15 of 43, 34.9%) 
patients developed a recurrent PSA infection (Figure 1b) at a 
median of 28 days (IQR, 10–33) after completion of treatment 
for the primary PSA infection: 9 of 15 (60%) presented a recur-
rence within 30 days, 5 of 15 (33.3%) between 31–60 days, and 1 
of 15 (6.7%) between 61 and 90 days. Recurrent PSA infections 
were observed equally among patients with primary BSI (5 of 
18, 27.8%), LRTI (8 of 19, 42.1%) and BSI + LRTI (2 of 6, 33.3%) 
(P = .65). Three (20%) patients had >1 recurrent PSA infections 
(Supplementary Table 3). In 13 of 15 patients, antibiograms for 
the primary and first recurrent PSA infection were available: 8 
of 13 (61.5%) patients had identical antibiograms between the 
2 episodes. In 5 of 13 (38.5%) patients, antibiograms differed: 
1, 2, and 1 patients developed resistance to cephalosporins, 
carbapenems, and fluoroquinolones, respectively. In 1 patient, 
an initially fluoroquinolone-resistant isolate in the primary 
episode was fluoroquinolone susceptible in the recurrent PSA 
infection.
Risk Factors for Recurrent Pseudomonas aeruginosa Infections
The independent variables evaluated as recurrence predictors 
in univariable analyses are presented in Supplementary Table 
4. Patients with recurrent PSA infections were more likely to 
have received shorter treatment courses for their primary in-
fection (median, 13 days; IQR, 11–16) compared with those 
without recurrence (median, 21 days; IQR, 14–31; P =  .04). 
Recurrent infections were observed in 6 of 30 (20%) versus 
9 of 13 (69.2%) patients, who received treatment for ≥14 
and <14  days, respectively (log rank  =  0.002) (Figure  1c). 
Recurrent infections were observed in 2 of 17 (11.7%) versus 
13 of 26 (50%) patients who received treatments for ≥21 
and <21  days, respectively (log rank  =  0.008) (Figure  1d). 
Longer treatment duration of the primary PSA infec-
tion (≥14 days, odds ratio [OR] = 0.11, P =  .004; ≥21 days, 
OR  =  0.11, P  =  .01) was the only significant factor protec-
tive against recurrent PSA infection. Considering the small 
number of cases and lack of other important predictors, 
multivariable analyses were not performed.
When the effect of treatment duration was assessed by type 
of primary PSA infection (BSI versus LRTI with or without 
BSI), recurrent infections were more likely to occur among pa-
tients with LRTI, who received treatment for <14 (7 of 10, 70%) 
versus ≥14 days (3 of 15, 20%) (log rank = 0.01) (Figure 1e). 
Likewise, recurrent infections were significantly more likely 
to occur among patients with PSA LRTI, who received treat-
ment for <21 (9 of 15, 60%) versus ≥21 days (1 of 10, 10%) (log 
rank = 0.01) (Figure 1f).
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All-Cause Mortality
All-cause mortality by day 14, 30, 60, and 90 post-PSA infec-
tion diagnosis was 10.9% (6 of 55), 12.7% (7 of 55), 18.2% (10 
of 55), and 23.6% (13 of 55), respectively. All-cause mortality 
was higher among patients with (35 of 55, 63.6%) versus those 
without PSA infection (494 of 1259, 39.2%; P  < .001). All-cause 
mortality was similar among patients with (7 of 15, 46.6%) and 






















































0 2 4 6







8 10 0 20 40 60






















































0 20 40 60
Days after primary PSA infection treatment completion
Treatment duration of  primary PSA infection <14 days
Treatment duration of  primary PSA infection ≥14 days
Primary PSA LRTI (±BSI), Treatment duration ≥14 days
Primary PSA LRTI (±BSI), Treatment duration <14 days
Primary PSA BSI only, Treatment duration <14 days
Primary PSA BSI only, Treatment duration ≥14 days
Primary PSA LRTI (±BSI), Treatment duration ≥21 days
Primary PSA LRTI (±BSI), Treatment duration <21 days
Primary PSA BSI only, Treatment duration <21 days
Primary PSA BSI only, Treatment duration ≥21 days
Treatment duration of  primary PSA infection <21 days
Treatment duration of  primary PSA infection ≥21 days
80 100 0 20 40 60



























0 20 40 60



























0 20 40 60





Figure 1. (a) Incidence of primary Pseudomonas aeruginosa (PSA) infections in a cohort of 1314 allogeneic hematopoietic cell transplant (HCT) recipients. (b) Ninety-day 
incidence of recurrent PSA infections among 43 allogeneic-HCT recipients after completion of treatment of their primary PSA infection. (c) Ninety-day incidence of recurrent 
PSA infections based on treatment duration of primary infection for <14 vs ≥14 days. (d) Ninety-day incidence of recurrent PSA infections based on treatment duration of pri-
mary infection for <21 vs ≥21. (e) Ninety-day incidence of recurrent PSA infections based on primary PSA infection type (bloodstream infection [BSI] only vs lower respiratory 
tract infection [LRTI] with and without BSI) and treatment duration of primary infection for <14 vs ≥14 days. (f) Ninety-day incidence of recurrent PSA infections based on 
primary PSA infection type (BSI only vs LRTI with and without BSI) and treatment duration of primary infection for <21 vs ≥21 days.
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DISCUSSION
In this retrospective, multicenter, 8-year, cohort study on the 
incidence of recurrent PSA infections in allo-HCT recipients, 
we report a high rate of infection recurrence particularly among 
patients who received shorter than 14-day treatment courses. 
One in three patients with primary PSA infection had a recur-
rence within the first 3 months after their primary PSA infec-
tion. This is higher than the 16% recurrence rate reported by 
the Seattle group more than 1 decade ago [4]. The higher rates 
of recurrent PSA infection observed in our cohort may be, in 
part, due to higher risk patients and HCT practices compared 
with prior decades, the higher numbers of LRTI included in this 
cohort (60% vs 30%), and more delayed post-HCT presentation 
(median: 9 vs 3 months) compared with the Seattle cohort. Later 
diagnosis could suggest that most patients were diagnosed in an 
outpatient setting, with longer times to healthcare presentation 
and treatment initiation leading to more dismal outcomes.
Our data confirm the findings by Hakki et al [4] that treat-
ment duration of <14  days for PSA infection may be asso-
ciated with higher recurrence rates in allo-HCT recipients. 
Treatment for a minimum of 2 weeks decreased the risk of 
recurrence, with an absolute risk reduction of almost 50% and 
a number needed to treat of 2 patients to prevent 1 recurrent 
infection. This observation becomes quite pertinent, during 
an era when shorter treatment courses are preferred for bacte-
rial pneumonias [7, 8]. In fact, recent data suggest that shorter 
(7–9 days) treatment duration may be adequate for the treat-
ment of Gram-negative (and PSA) bacteremia [9, 10]. It is 
notable that only a few allo-HCT recipients were included in 
those studies, which did not allow researchers to make any 
further conclusions on treatment duration in high-risk allo-
HCT recipients. Moreover, our data suggest that treatment 
courses as long as 3 weeks may prevent disease recurrence 
even further, particularly among HCT recipients with PSA 
LRTI (with and without bacteremia). It is likely that certain 
patients with PSA LRTI may have higher organism inoculum, 
requiring prolonged treatment duration for sufficient source 
control and adequate lung tissue penetration. Whether longer 
than 2-week treatment courses are required for patients with 
PSA LRTI versus BSI requires further research.
CONCLUSIONS
This study has several limitations, including its retrospective 
nature and limited sample size. Molecular typing was not per-
formed; therefore, definitive evidence of infection recurrence 
due to the same isolate was not established. However, based 
on the timing of most recurrent infections within the first 
2  months of the primary event and similar antibiograms in 
more than 60% of the cases, we believe that they represent true 
recurrences. In conclusion, PSA infections in allo-HCT recipi-
ents are associated with high recurrence rates, and a minimum 
of 14 days of targeted antibiotic treatment seems to be required 
to prevent recurrent infections. Further prospective studies are 
needed to evaluate these findings and define the optimal dura-
tion of treatment to prevent infection recurrence.
Supplementary Data
Supplementary materials are available at Open Forum Infectious Diseases 
online. Consisting of data provided by the authors to benefit the reader, 
the posted materials are not copyedited and are the sole responsibility 
of the authors, so questions or comments should be addressed to the 
corresponding author.
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